199 related articles for article (PubMed ID: 25415226)
1. WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase 1.
Chang YF; Hsu YF; Chiu PT; Huang WJ; Huang SW; Ou G; Sheu JR; Hsu MJ
Oncotarget; 2015 Jan; 6(1):85-100. PubMed ID: 25415226
[TBL] [Abstract][Full Text] [Related]
2. The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death.
Huang YH; Huang SW; Hsu YF; Ou G; Huang WJ; Hsu MJ
Sci Rep; 2015 Oct; 5():15900. PubMed ID: 26510776
[TBL] [Abstract][Full Text] [Related]
3. WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.
Chuang YF; Huang SW; Hsu YF; Yu MC; Ou G; Huang WJ; Hsu MJ
Br J Pharmacol; 2017 Sep; 174(17):2941-2961. PubMed ID: 28646512
[TBL] [Abstract][Full Text] [Related]
4. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
5. WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-inflammatory properties via MKP-1 in LPS-stimulated RAW264.7 macrophages.
Chen WC; Yen CS; Huang WJ; Hsu YF; Ou G; Hsu MJ
Br J Pharmacol; 2015 Apr; 172(7):1894-908. PubMed ID: 25521622
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
7. WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade.
Huang SW; Yang HY; Huang WJ; Chen WC; Yu MC; Wang SW; Hsu YF; Hsu MJ
Front Oncol; 2019; 9():1188. PubMed ID: 31781495
[No Abstract] [Full Text] [Related]
8. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
10. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
Li X; Wang X; Ye H; Peng A; Chen L
Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
[TBL] [Abstract][Full Text] [Related]
11. PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.
Huang SW; Lien JC; Kuo SC; Huang TF
Br J Pharmacol; 2014 Dec; 171(24):5728-42. PubMed ID: 25091695
[TBL] [Abstract][Full Text] [Related]
12. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
Su M; Huang J; Li J; Qin X; Tang X; Jin F; Chen S; Jiang C; Zou Z; Peng K; Nuruzzaman M; Zhang J; Luo J; Liu S; Luo Z
Oncotarget; 2016 Apr; 7(14):19018-30. PubMed ID: 26967559
[TBL] [Abstract][Full Text] [Related]
13. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer activity of an osthole derivative, NBM-T-BMX-OS01: targeting vascular endothelial growth factor receptor signaling and angiogenesis.
Yang HY; Hsu YF; Chiu PT; Ho SJ; Wang CH; Chi CC; Huang YH; Lee CF; Li YS; Ou G; Hsu MJ
PLoS One; 2013; 8(11):e81592. PubMed ID: 24312323
[TBL] [Abstract][Full Text] [Related]
15. Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis.
Moraes MS; Costa PE; Batista WL; Paschoalin T; Curcio MF; Borges RE; Taha MO; Fonseca FV; Stern A; Monteiro HP
Arch Biochem Biophys; 2014 Sep; 558():14-27. PubMed ID: 24960080
[TBL] [Abstract][Full Text] [Related]
16. Coral-derived compound WA-25 inhibits angiogenesis by attenuating the VEGF/VEGFR2 signaling pathway.
Lin SW; Huang SC; Kuo HM; Chen CH; Ma YL; Chu TH; Bee YS; Wang EM; Wu CY; Sung PJ; Wen ZH; Wu DC; Sheu JH; Tai MH
Mar Drugs; 2015 Feb; 13(2):861-78. PubMed ID: 25668036
[TBL] [Abstract][Full Text] [Related]
17. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
18. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
19. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
20. Ethyl cinnamate suppresses tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in colorectal cancer.
Wang S; Yang J; Kuang X; Li H; Du H; Wu Y; Xu F; Liu B
J Ethnopharmacol; 2024 May; 326():117913. PubMed ID: 38360380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
